| Authors: |
Stopforth RJ; Antibody and Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, United Kingdom., Oldham RJ; Antibody and Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, United Kingdom., Tutt AL; Antibody and Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, United Kingdom., Duriez P; Southampton Experimental Cancer Medicine/Cancer Research U.K. Centre, Protein Core Facility, Cancer Sciences Unit, Southampton General Hospital, Southampton SO16 6YD, United Kingdom., Chan HTC; Antibody and Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, United Kingdom., Binkowski BF; Promega Corp., Fitchburg, WI 53711., Zimprich C; Promega Corp., Fitchburg, WI 53711., Li D; Promega Corp., Fitchburg, WI 53711., Hargreaves PG; Promega UK Ltd., Southampton Science Park, Southampton SO16 7NS, United Kingdom., Cong M; Promega Corp., Fitchburg, WI 53711., Reddy V; Division of Medicine, Centre for Rheumatology, University College London, London WC1E 6JF, United Kingdom; and., Leandro MJ; Division of Medicine, Centre for Rheumatology, University College London, London WC1E 6JF, United Kingdom; and., Cambridge G; Division of Medicine, Centre for Rheumatology, University College London, London WC1E 6JF, United Kingdom; and., Lux A; Department of Biology, University of Erlangen-Nuremberg, 91058 Erlangen, Germany., Nimmerjahn F; Department of Biology, University of Erlangen-Nuremberg, 91058 Erlangen, Germany., Cragg MS; Antibody and Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, United Kingdom; msc@soton.ac.uk. |